Asian Spectator


The Times

.

LANDMARK’s ‘Destination CENTRAL’ Opens an Inspiring New Chapter for the Festive Season in Hong Kong

Heightening the Global Momentum of Louis Vuitton’s Monumental Façade and Welcoming the Arrival of “Christmas at The Gloucester Hotel”HONG KONG SAR – Media OutReach News...

DHL Loses Contract and Intellectual Property Trial to US Tech ...

TRENTON, New Jersey, July 24, 2018 /PRNewswire-AsiaNet/ -- -- Jury finds DHL liable for copyright infringement and violation of the covenant of Good Faith and Fair Dealing.A jury in the Unit...

Charging Up Confidence: Aftersales Service Is Key To EV Trust

Amidst a slowdown in the electric vehicle (EV) market, automakers like VinFast are doubling down on after-sales services to instill confidence and win over hesitant consumers.HANOI, VIETNAM ...

Commerce Dot Com Leads CSR Effort to Celebrate Ramadan with Lanoh Tribe

PERAK, MALAYSIA - Media OutReach Newswire - 27 March 2025 - The residents of Kampung Air Bah, Lenggong, Perak; mostly Muslims from the Lanoh indigenous tribe warmly welcomed the visit ...

Temus Becomes Singapore’s First OutSystems Premier Partner, Accelerating Low-Code Adoption Amid Surging Demand

SINGAPORE - Media OutReach Newswire - 10 March 2025 - Temus, a Singapore-based digital transformation consultancy, has become the first OutSystems Premier Partner in Singapore. This milest...

How One Man's Love Affair With Pokémon Made This Father the Wo...

DALLAS, July 14, 2021 /PRNewswire-Asianet/ -- -- Collection amassed by the late Bart Kiser offered in Heritage Auctions' inaugural Trading Card Games Auction July 24-25Pokémon was big...

Hang Lung’s Heartland 66 in Wuhan Wins Gold Award in Best Mixed-used Development Category at MIPIM Asia Awards 2022

HONG KONG SAR - Media OutReach - 8 December 2022 - Hang Lung Properties is pleased to announce that Heartland 66, Wuhan, its first large-scale commercial development in central China, has w...

VIOMI Launches New AI Water Purifier inno in Malaysia, Appoints Shila Amzah as Brand Ambassador

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 29 October 2025 - VIOMI, a leading global brand specializing in AI-driven water purification technology, officially launched its latest co...

Ashford Dental opens third branch in Bedok, specialising in same-day smile restoration

SINGAPORE - Media OutReach - 23 November 2020 - With the opening of their third facility in Bedok projected for end December 2020, the Ashford Dental Centre is expan...

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent.

This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI:12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17).

The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte. The antitumor effect of denileukin diftitox depends on the intracellular delivery of diphtheria toxin which inhibits protein synthesis and induces cell death. The agent has been evaluated as a drug with high medical need by the "Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Needs"(1), and Eisai has been requested to develop it by the Ministry of Health, Labour and Welfare.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) The Study Group set up within the Ministry of Health, Labour and Welfare with the purpose of contributing to enhancing the development of drugs and indications that have not been approved in Japan (unapproved drugs/off-label drugs) by pharmaceutical companies. In addition to evaluating the medical needs of unapproved drugs/off-label drugs, their responsibilities include evaluating the applicability of the drug to an Application with Public Knowledge, and the adequacy of additional clinical studies that need to be conducted for filing applications for approval, and so on.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalzlibraryzlibraryuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girişStreamEastStreamEastjojobetcialis 20 mg fiyat